非那雄胺在晚期前列腺癌间歇性雄激素阻断治疗间隙期的应用

Study of finasteride application during the off-cycle in patients with advanced prostate cancer treated with intermittent androgen blockade

目的研究非那雄胺在晚期前列腺癌间歇性雄激素阻断（IAB）治疗间隙期的应用是否能延缓晚期前列腺癌的疾病进展。方法87例晚期前列腺癌患者分2组，A组49例行单纯IAB治疗，B组38例在IAB治疗的基础上间歇期采用非那雄胺治疗。比较2组患者的疾病治疗周期和疾病进展时间。结果A组患者共完成89个治疗周期，平均治疗周期为（12．8±5．4）个月，其中治疗期为（6．6±3．5）个月，间歇期为（7．1±4．8）个月；B组患者共完成85个治疗周期，平均治疗周期为（15．3±5．9）个月，其中治疗期为（6．9±3．2）个月，间歇期为（9．2±3．9）个月；B组治疗周期和间歇期长度大于A组（P=0．0428，P=0．03）。B组3年疾病进展率（28．4±2．7）％，低于A组的（34．8±3．5）％（P=0．0350）。结论非那雄胺在晚期前列腺癌间歇性IAB间隙期的应用能延缓晚期前列腺癌的疾病进展。

Objective To investigate the finasteride application during the off cycle of intermittent androgen blockade （IAB） in patients with advanced prostate cancer treated with IAB. Methods Eighty-seven patients with advanced prostate cancer were divided into two groups： forty nine patients received IAB （group A）, and thirty eight patients underwent IAB and finasteride during the off-cycle of lAB （group B）. The time of treatment cycle and the time to disease progression were compared between the two groups. Results The patients in group A completed 89 treatment cycles and the mean cycle length was （12.8 ±5.4） months [treatmcnt time and non-treatment time were （6.6±3.5） months and （7.1±4.8） months, respectively]. The patients in group B completed 85 cycles and the mean cycle length was （15.3 ±5.9） months [treatment time and non-treatment time were （6.9±3.2） months and （9.2±3.9） months, respectively]. There was a significant difference between group A and B in the mean cycle length and the non treatment time （P 0. 0428 ,P= 0.03）. The 3-year progression rate was（34.8 ± 3.5）% in group A and（28.4 ± 2.7）% in groups B （P= 0. 035）. Conclusions The application of finasteride during the off-cycle of IAB in patients with advanced prostate cancer treated with intermittent androgen blockade （IAB） can delay progression of advanced prostate cancer.